Agilent, PL1580-3350, AdvanceBio SEC 130Å, 4.6 x 150 mm, 2.7 µm, LC column

AdvanceBio SEC 130Å, 4.6 x 150 mm, 2.7 µm, LC column. A size exclusion column for efficient aggregate analysis of peptides and small proteins. The resolving range is 0.1-120 kDa.

Specifications:
Brand: AdvanceBio SEC
Hardware: SS
Inner Diameter (ID): 4.6 mm
LC Platform: Stainless Steel
Length: 150 mm
Maximum Temperature: 80 °C
Molecular Weight Lower Limit: 100 Da
Molecular Weight Upper Limit: 120000 Da
Part Number Application Domain: Biopharma
Part Number Application: Aggregate & Fragment AnalysisMonoclonal Antibodies (mABs)PeptidesProteins
Particle Size: 2.7 µm
Particle Type: Fully Porous
Phase: SEC
Pore Size: 130 Å
Pressure Rating: 400 bar
Separation Mode: Size Exclusion (SEC)
Shipping Solvent: 0.02% Sodium Azide
Technique: LC
UNSPSC Code: 41115711
pH Range: 2-8.5

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
The AdvanceBio SEC 130Å, 4.6 x 150 mm, 2.7 µm LC column is specifically designed for high-resolution size exclusion chromatography of biomolecules, offering precise analysis of proteins, monoclonal antibodies, and other biotherapeutic samples. Utilizing advanced 2.7 µm particle technology with a 130 angstrom pore size, this column enables superior separation efficiency, sharp peak resolution, and fast analysis times, making it ideal for both routine quality control and research applications in biopharmaceutical development.

It is optimized for use with a wide range of liquid chromatography systems, including Agilent's 1100, 1200, and 1260 Infinity series, as well as other industry-standard HPLC and UHPLC instruments. The robust hardware and inert materials ensure reliable performance and reproducibility across multiple runs. Key usage scenarios include aggregate quantification, molecular weight determination, and characterization of fragment and oligomer content in complex biologics.

This column integrates seamlessly with Agilent’s AdvanceBio SEC mobile phases and related SEC columns for a unified analytical workflow. It is suitable for analytical, characterization, and comparability studies, supporting regulatory submissions and process development for therapeutic proteins and antibody-based drugs.